Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)

Lundbeck

Status and phase: Terminated; Phase 2

Conditions: Primary Insomnia

Treatments: Drug: MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose); Drug: Placebo / Duration of Treatment: 2 days for screening period

Study type: Interventional

Funder types: Industry

Identifiers

NCT00266357

2005_107

0928-041

Details and patient eligibility

About

A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.

Sex: All

Ages: 20 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a diagnosis of primary insomnia

Exclusion criteria

• Patients with an active psychiatric disorder other than primary insomnia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind